PCSK9 Patent Case: Praluent Injunction Vacated, But May Well Return

Appeals court vacates injunction that Repatha marketer Amgen had won against Sanofi/Regeneron's Praluent, but notes 'a reduction in choice of drugs cannot be the sole reason for a district court to deny an injunction.'

A patent holder's request for a permanent injunction cannot be denied simply because removing an infringing drug from the market would reduce the number of available treatments, the federal appeals court ruled in a PCSK9 inhibitor patent dispute.

In an Oct. 5 opinion, a three-judge panel of the US Court of Appeals for the Federal Circuit unanimously...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet